2022 - Adverse Events Management and Interstitial Lung Disease (ILD) Detection Project

Background

Interstitial lung disease (ILD) is an issue in many cancers and cancer treatments. With the development of immunotherapies, it has become a focus of attention, but it is an historical issue related to radiation, busulfan and bleomycin.

Many treatments in various disease areas have ILD as a potential toxicity. Early diagnosis is crucial to avoid irreversible damage or even death of the patient.

Project Goals

The aim of this project is to expand awareness and knowledge among HPCs about:

- The frequency of ILD with various oncological treatments
- Patients at major risk and methods, if any, to avoid ILD
- The appropriate methods for the early diagnosis of ILD, with or without sophisticated radiological methods
- Treatment of ILD and possible reinstatement of the oncological drug

Project Target Group

HCPs - Medical Oncologists – Haematologists - Radiation Oncologists – Pulmonologists - Radiologists

Project Approach and Outcomes

This multi-step project will consist of:

- An online Task Force

- A Scientific Position Statement, published on the Cancerworld magazine

- Five Podcasts

- A series of Educational Webinars

- A Virtual Event

The materials - free of charge and accessible to the audience by registering on SPCC's OncoCorner e-learning platform - will remain available on-demand on the platform.

Task Force - 25 April 2022

An online Task Force (closed session, not accessible to the audience) organized to discuss new strategies to tackle adverse events on Interstitial Lung Disease cancer.

Renowned experts were invited to join the faculty:

- Experts from ESR (European Society of Radiology)
- Authors of recent publications in the field

- 1 Cancerworld journalist

- Scientific Position Statement

The most important results of the Task Force have been summarised in a scientific article published on the Cancerworld magazine. To read the full article please click here.

Acknowledgements

Sharing Progress in Cancer Care wishes to express its appreciation to AstraZeneca and Daiichi Sankyo for their unrestricted educational grants.

Podcast